<!--The Official Report of Parliamentary Debates (Hansard) of the Legislative Council and the House of Assembly of the Parliament of South Australia are covered by parliamentary privilege. Republication by others is not afforded the same protection and may result in exposure to legal liability if the material is defamatory. You may copy and make use of excerpts of proceedings where (1) you attribute the Parliament as the source, (2) you assume the risk of liability if the manner of your use is defamatory, (3) you do not use the material for the purpose of advertising, satire or ridicule, or to misrepresent members of Parliament, and (4) your use of the extracts is fair, accurate and not misleading. Copyright in the Official Report of Parliamentary Debates is held by the Attorney-General of South Australia.-->
<hansard id="" tocId="" xml:lang="EN-AU" schemaVersion="1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xml="http://www.w3.org/XML/1998/namespace" xmlns:xsi="http://www.w3.org/2007/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:noNamespaceSchemaLocation="hansard_1_0.xsd">
  <name>Legislative Council</name>
  <date date="2015-05-07" />
  <sessionName>Fifty-Third Parliament, Second Session (53-2)</sessionName>
  <parliamentNum>53</parliamentNum>
  <sessionNum>2</sessionNum>
  <parliamentName>Parliament of South Australia</parliamentName>
  <house>Legislative Council</house>
  <venue></venue>
  <reviewStage>published</reviewStage>
  <startPage num="609" />
  <endPage num="643" />
  <dateModified time="2022-08-06T14:30:00+00:00" />
  <proceeding continued="true">
    <name>Answers to Questions</name>
    <subject>
      <name>Macular Degeneration</name>
      <text id="201505077bdad9983c184ae2a0000544">
        <inserted>
          <heading>Macular Degeneration</heading>
        </inserted>
      </text>
      <talker role="member" id="4364" kind="question">
        <name>The Hon. K.L. VINCENT</name>
        <house>Legislative Council</house>
        <questions>
          <question date="2015-05-07">
            <name>Macular Degeneration</name>
          </question>
        </questions>
        <text id="201505077bdad9983c184ae2a0000545">
          <inserted>In reply to <by role="member" id="4364">the Hon. K.L. VINCENT </by>(11 February 2015).  </inserted>
        </text>
      </talker>
      <talker role="member" id="1821" kind="answer">
        <name>The Hon. G.E. GAGO</name>
        <house>Legislative Council</house>
        <electorate id="">Minister for Employment, Higher Education and Skills, Minister for Science and Information Economy, Minister for the Status of Women, Minister for Business Services and Consumers</electorate>
        <questions>
          <question date="2015-05-07">
            <name>Macular Degeneration</name>
          </question>
        </questions>
        <text id="201505077bdad9983c184ae2a0000546">
          <inserted>
            <by role="member" id="1821">The Hon. G.E. GAGO (Minister for Employment, Higher Education and Skills, Minister for Science and Information Economy, Minister for the Status of Women, Minister for Business Services and Consumers):</by>  I have been advised:</inserted>
        </text>
        <text id="201505077bdad9983c184ae2a0000547">
          <inserted>'Wet' and 'Dry' are terms applied to late stage Age-related Macular Degeneration (AMD). Wet AMD requires expensive monthly injections, whereas there is no current treatment for Dry AMD. </inserted>
        </text>
        <text id="201505077bdad9983c184ae2a0000548">
          <inserted>The research trialling Ellex Medical's Retinal Rejuvenation Therapy is targeting the early stages of AMD, for which there is no current treatment available. If the trial is successful, it will have the potential to delay the progression of the disease and thereby reduce the massive burden of treatment to patients, their families, and the whole health care system</inserted>
        </text>
        <text id="201505077bdad9983c184ae2a0000549" />
      </talker>
    </subject>
  </proceeding>
</hansard>